---
title: "Virax Biolabs Group Limited (VRAX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/VRAX.US.md"
symbol: "VRAX.US"
name: "Virax Biolabs Group Limited"
industry: "醫療產品分銷商"
---

# Virax Biolabs Group Limited (VRAX.US)

| Item | Detail |
|------|--------|
| Industry | 醫療產品分銷商 |
| Location | 美股市場 |
| Website | [viraxbiolabs.com](https://viraxbiolabs.com) |

## Company Profile

Virax Biolabs Group Limited 是一家生物技術公司，專注于分發用于病毒疾病預防、檢測、診斷和風險管理的診斷測試工具，特別是在 T 細胞體外診斷領域。該公司提供多種體外診斷測試工具，包括呼吸道、懷孕與生育、傳染病、性傳播感染、藥物濫用、腫瘤、心臟病、女性健康等測試工具，均在 ViraxClear 品牌下；並且在 ViraxVet 品牌下提供小動物獸醫診斷的快速和分子測試。它還提供 ViraxImmune，一種 T 細胞體外診斷設備和健康移動應用；以及服務，如抗體工程、定制肽、蛋白質測序、疫苗有效性測試、免疫學實驗室服務、試劑盒和試劑。此外，該公司還參與研發活動；並提供採購...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:10.000Z

**Overall: D (0.70)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 15 / 15 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -96.48% |  |
| Net Profit YoY | 14.24% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.29 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.53M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2986.00 |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -80.87% | E |
| Profit Margin | -189001.71% | E |
| Gross Margin | 80.10% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -96.48% | E |
| Net Profit YoY | 14.24% | C |
| Total Assets YoY | -39.48% | E |
| Net Assets YoY | -39.72% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.05% | D |
| OCF YoY | -96.48% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 11.23% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Virax Biolabs Group Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-80.87%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-189001.71%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "80.10%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-96.48%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "14.24%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-39.48%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-39.72%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.05%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-96.48%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "11.23%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Cencora (US.COR) | B | B | A | E | B | B |
| 02 | 亨利香恩 (US.HSIC) | B | C | A | D | B | B |
| 03 | 麥克森 (US.MCK) | E | B | A | E | A | C |
| 04 | 卡地納健康 (US.CAH) | E | B | A | E | A | C |
| 05 | AdaptHealth (US.AHCO) | C | C | B | D | B | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.27 | 7/13 | - | - | - |
| PB | 0.29 | 2/13 | 0.62 | 0.49 | 0.41 |
| PS (TTM) | 513.62 | 12/13 | 635.69 | 407.93 | 53.97 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-09T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.21 |
| Highest Target | 1.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/VRAX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/VRAX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/VRAX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.